The Burzynski Research Institute is located a short drive from the Clinic. There, antineoplastons are manufactured and research is ongoing. Although the detailed mechanism by which antineoplastons work is unknown, they may act as biochemical microswitches to turn off the genes that cause cancer, called oncogenes , and activate the genes that fight cancer, called tumor suppressor genes . Because these drugs are harmless to healthy cells the body can be flooded with antineoplastons, and only cancer cells are affected. Patients typically carry a small pump that delivers antineoplastons directly into the bloodstream at regular intervals.
Some patients take capsules orally.
Recent clinical trials have shown particularly encouraging results in malignant brain tumors and non-Hodgkin's lymphoma. Most of these patients had already failed chemotherapy and radiation therapy and had no remaining conventional treatment options. Researchers at Kurume University in Japan are conducting two clinical trials on antineoplastons in the treatment of colon cancer and primary liver cancer, which are major killers in that country. These researchers already have reported successful outcomes in both types of cancer. At the S.R. Burzynski Clinic, clinical trials are underway for many types of cancer.